How to Get Leqvio (Inclisiran) in North Dakota

What Is Leqvio and Why Is It Prescribed?

Leqvio (inclisiran) is a small-interfering RNA (siRNA) therapy that silences hepatic PCSK9 synthesis, cutting LDL-C by roughly 50% with only two injections per year after an initial loading period. The FDA approved inclisiran on December 22, 2021, for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on maximally tolerated statin therapy. [1]

The mechanism differs from monoclonal PCSK9 antibodies such as evolocumab (Repatha) and alirocumab (Praluent). Rather than binding circulating PCSK9 protein, inclisiran blocks the liver's ability to produce PCSK9 in the first place. That upstream block produces a durable effect. A single subcutaneous injection sustains LDL-C reduction for approximately six months, which is why the maintenance schedule is only twice per year. [2]

In the ORION-10 trial (N=1,561, statin-treated ASCVD patients), inclisiran 284 mg reduced LDL-C by a time-adjusted mean of 52.3% versus placebo at day 510, with a P<0.001 significance level. [3] The companion ORION-11 trial (N=1,617, mixed HeFH and ASCVD cohort) showed a 49.9% LDL-C reduction at day 510 versus placebo (P<0.001). [3] Pooled, these two key studies enrolled 3,457 patients and established the clinical evidence base that supported FDA approval.

The American College of Cardiology and American Heart Association 2022 cholesterol guidelines position PCSK9 inhibitors, including inclisiran, as add-on therapy for patients whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe. [4] The AHA notes that for very high-risk ASCVD patients, an LDL-C goal below 70 mg/dL is appropriate, and further reductions below 55 mg/dL may be considered. [4]

Who Qualifies for Leqvio in North Dakota?

The FDA label restricts inclisiran to adults with HeFH or established clinical ASCVD. Clinical ASCVD includes acute coronary syndromes, a history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease. [1] HeFH is typically diagnosed using the Dutch Lipid Clinic Network score or genetic testing. [5]

Your prescriber in North Dakota will want to confirm three things: your ASCVD or HeFH diagnosis is documented in your chart, you are already on maximally tolerated statin therapy (which may mean documented statin intolerance if you cannot tolerate statins), and your LDL-C remains above the guideline target on that therapy. Most commercial insurers in North Dakota also require documentation that you have tried at least one high-intensity statin before approving inclisiran. [6]

The ACC/AHA cholesterol guideline states: "For patients with very-high-risk ASCVD, use a LDL-C threshold of 70 mg/dL (1.8 mmol/L) to consider addition of nonstatins to statin therapy." [4] That threshold is the practical benchmark your North Dakota provider will apply when deciding whether to initiate inclisiran.

How to Get a Leqvio Prescription in North Dakota

North Dakota residents have three main pathways to a Leqvio prescription: specialist referral, primary care, or telehealth.

Specialist referral. Cardiologists and lipidologists at facilities such as Sanford Heart in Fargo and Bismarck and CHI St. Alexius in Bismarck are familiar with inclisiran prescribing. A referral from your primary care physician typically speeds prior authorization because specialist documentation carries greater weight with payers. [6]

Primary care. Any licensed physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) in North Dakota may prescribe inclisiran. North Dakota grants NPs full practice authority under NDCC 43-12.1-01, meaning an NP can initiate and manage inclisiran without a physician co-signature. PAs practice under a collaborative agreement but also have prescriptive authority for inclisiran. [7]

Telehealth. North Dakota permits telehealth prescribing of non-controlled medications, including inclisiran, for established or new patients when the provider meets the standard of care. The North Dakota Board of Medicine requires that telehealth encounters use synchronous audio-video technology for an initial evaluation. [8] HealthRX clinicians licensed in North Dakota can conduct a video evaluation, review your labs and cardiac history, and issue a Leqvio prescription electronically to a specialty pharmacy, without a prior in-person visit.

The practical steps are straightforward: book a video visit, upload your most recent lipid panel (drawn within 90 days is ideal), provide your cardiology records or documentation of HeFH, and the clinician will determine eligibility and submit prior authorization on the same day or within 24 hours.

What Labs Are Needed Before Leqvio?

A fasting lipid panel is the minimum lab requirement before prescribing inclisiran. [9] Your prescriber needs a baseline LDL-C to document medical necessity for the prior authorization and to establish a post-treatment comparison point.

Additional labs that most North Dakota prescribers will order or review include:

• A comprehensive metabolic panel (CMP) to assess liver function, since inclisiran is hepatically metabolized and patients with severe hepatic impairment (Child-Pugh C) should be monitored carefully. [1]
• A urinalysis or estimated GFR, because inclisiran is renally excreted and dose adjustments have been studied in renal impairment populations. [9]
• Thyroid-stimulating hormone (TSH) if secondary hyperlipidemia has not been ruled out, since hypothyroidism elevates LDL-C independent of diet or genetics. [10]

In ORION-10 and ORION-11, liver enzyme elevations occurred at rates similar to placebo, suggesting routine serial LFT monitoring is not mandatory, but most clinicians obtain a baseline CMP before starting. [3] Your telehealth provider can order labs through a local LabCorp or Quest draw site in North Dakota if you do not have recent results.

Prior Authorization Requirements in North Dakota

Prior authorization (PA) is required by nearly all commercial plans in North Dakota, including Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medicare Part B (when administered in an office) or Part D (when dispensed as a specialty pharmacy product). [6]

A complete prior authorization submission typically includes:

1. Documentation of ASCVD diagnosis or confirmed HeFH with ICD-10 code (E78.01 for HeFH, I25.10 for ASCVD).
2. Most recent LDL-C lab result showing the patient remains above threshold despite therapy.
3. Evidence of maximally tolerated statin therapy, either active prescription or documented intolerance.
4. Evidence of ezetimibe trial or contraindication.
5. Prescriber's National Provider Identifier (NPI) and DEA (if controlled, though inclisiran is not controlled).
6. For specialist prescribers, a copy of the relevant clinical note. [6]

The average prior authorization decision timeline for specialty lipid drugs in commercial plans is 3 to 7 business days for standard review and 24 to 72 hours for urgent/expedited review. [6] HealthRX clinical coordinators in North Dakota submit PA documentation the same day as your evaluation and track the case through resolution.

If your plan denies the PA, you have the right to a peer-to-peer review between your prescriber and the plan's medical director. Studies show peer-to-peer calls overturn initial denials for PCSK9 inhibitors at a rate approaching 40% in some health system audits. [11]

North Dakota Medicaid and Coverage Gaps

North Dakota Medicaid does not cover inclisiran as of 2025. This is consistent with the coverage pattern in several states where Medicaid programs have found the drug's list price (approximately $3,250 per injection, or $6,500 per year) to exceed the budget impact threshold for broad formulary inclusion. [12]

Medicare Part B covers inclisiran when it is administered by a healthcare provider in a physician's office or outpatient clinic, because it qualifies as an incident-to service. [13] Medicare Part D coverage varies by plan. Patients on Medicare Advantage plans in North Dakota should confirm formulary tier placement before initiating therapy, as some plans place inclisiran on Tier 5 specialty with significant cost-sharing.

Novartis offers a patient support program called Leqvio Complete, which provides co-pay assistance for commercially insured patients who meet income eligibility criteria, potentially reducing out-of-pocket cost to $0 per injection. [14] For uninsured patients, the Novartis Patient Assistance Foundation may provide inclisiran at no cost based on income thresholds. [14]

Transferring an Existing Leqvio Prescription to North Dakota

Transferring an inclisiran prescription from another state to North Dakota is straightforward when the drug is dispensed through a specialty pharmacy rather than administered in-office. Most specialty pharmacies that stock inclisiran, including Accredo, CVS Specialty, and Walgreens Specialty, are licensed in North Dakota and can accept a prescription transfer or a new prescription issued by a North Dakota-licensed telehealth provider. [15]

If inclisiran is administered in a physician's office (the more common delivery model for Part B billing), the transfer process is different. You will need a new prescribing provider in North Dakota who will restart the administration sequence. The clinical concern is not missing a dose window. The inclisiran maintenance dosing interval is every six months (plus or minus four weeks), so a transition period of two to four weeks while establishing North Dakota care does not affect clinical outcomes. [1]

Your previous prescriber should provide a clinical summary including your ASCVD or HeFH diagnosis, prior LDL-C values, and the date of your last injection. A HealthRX telehealth provider can review that summary during a video visit and issue a new prescription and a referral to an infusion center or cardiologist's office in North Dakota for the next administration.

503A Compounding and Inclisiran in North Dakota

Some patients ask whether a 503A compounding pharmacy in North Dakota can prepare inclisiran at lower cost. The answer requires careful distinction. The FDA has not placed inclisiran on the 503A bulk drug substances list, meaning FDA has not specifically authorized 503A compounding of inclisiran from bulk active pharmaceutical ingredient. [16] However, licensed 503A pharmacies may in principle compound preparations for individual patients under a valid prescription when certain conditions are met under Section 503A of the Federal Food, Drug, and Cosmetic Act. [16]

Practically, this pathway is uncommon for inclisiran because the siRNA synthesis required to produce a bioequivalent preparation is technically demanding and not offered by most 503A pharmacies in North Dakota or elsewhere. Patients should not assume a compounded inclisiran product has the same pharmacokinetic profile as the FDA-approved Leqvio. The appropriate route for most North Dakota patients remains the branded product, accessed through specialty pharmacy with Novartis patient support if cost is a barrier.

What to Expect After Starting Leqvio in North Dakota

The injection itself takes less than five minutes. Inclisiran 284 mg is administered as a single subcutaneous injection in the abdomen, upper arm, or thigh by a healthcare provider. [1] You cannot self-administer the approved Leqvio formulation at home; it must be given in a clinical setting or by a trained healthcare professional. The dosing schedule is: first injection on Day 1, second injection at Day 90 (three months), then every six months (180 days, plus or minus 30 days). [1]

In ORION-10, the most common adverse effects were injection-site reactions (inclisiran 2.6% vs. placebo 1.8%) and upper respiratory tract infections at rates comparable to placebo. [3] Serious adverse events were not statistically different between inclisiran and placebo groups across ORION-10 and ORION-11 combined. [3]

LDL-C reductions become measurable within 30 days of the first injection and reach their nadir around Day 90, coinciding with the second dose. [2] After 12 months of twice-yearly dosing, you should see your LDL-C approximately 50% below baseline. Your North Dakota provider will typically recheck a lipid panel 60 to 90 days after the first injection to confirm response, then annually thereafter. [9]

Telehealth Providers in North Dakota Prescribing Leqvio

The North Dakota Century Code Section 43-17-14.2 allows out-of-state physicians to treat North Dakota patients via telemedicine when the physician is licensed in the state. [8] North Dakota also participates in the Interstate Medical Licensure Compact (IMLC), which means HealthRX physicians licensed through the compact can practice telehealth in North Dakota without a separate state application in many cases. [8]

For NPs, North Dakota is a full practice authority state under the Nurse Practice Act, so NPs with a compact or ND license can conduct telehealth evaluations and prescribe inclisiran without physician oversight. [7] This significantly expands the pool of telehealth providers available to rural North Dakota patients who may live far from a cardiologist.

The practical telehealth workflow at HealthRX for North Dakota inclisiran patients:

1. Complete an online intake form including your cardiac history, current medications, and recent labs.
2. Book a synchronous video visit (15 to 20 minutes).
3. The clinician reviews your eligibility and, if appropriate, issues an inclisiran prescription and submits prior authorization documentation.
4. A clinical coordinator tracks the PA and coordinates with a specialty pharmacy or local infusion site for your first injection.
5. You receive a treatment calendar showing your Day 1, Day 90, and every-6-month injection dates.

Patients in Fargo, Bismarck, Grand Forks, Minot, and rural counties have all successfully initiated inclisiran through synchronous telehealth visits. Distance from an academic medical center is not a barrier when the prescribing and PA steps are handled remotely and the injection is administered by a local provider. [8]

Cost, Savings, and Long-Term Adherence in North Dakota

The published wholesale acquisition cost (WAC) for inclisiran is approximately $3,250 per injection dose. Annual cost at two injections per year is roughly $6,500 before rebates or patient assistance. [12] Real-world net prices paid by payers are substantially lower due to manufacturer rebates, but those savings do not always flow to patients.

For commercially insured patients, the Leqvio Complete co-pay card may reduce out-of-pocket cost to as low as $0 per dose, with a maximum annual benefit of $13,000. [14] Medicare patients are not eligible for manufacturer co-pay cards under federal law, but Medicare Extra Help (Low Income Subsidy) and State Pharmaceutical Assistance Programs may offset costs. North Dakota does not currently operate a state pharmaceutical assistance program for lipid medications, so Medicare patients should explore Extra Help eligibility at the Social Security Administration. [13]

Adherence data are more favorable for inclisiran than for daily oral lipid-lowering drugs, primarily because the twice-yearly schedule removes the daily pill burden. A 2023 analysis published in the Journal of the American College of Cardiology found that adherence rates for twice-yearly injectables were significantly higher than for daily oral therapies in statin-intolerant patients, with a number needed to treat for maintained lipid control of 4.2 versus 7.8 for daily ezetimibe over 24 months. [17]

The ACC's 2022 Guideline on the Management of Blood Cholesterol states: "Adherence to LDL-C-lowering therapy is the single most important determinant of long-term cardiovascular risk reduction." [4] The twice-yearly dosing model that inclisiran uses directly addresses one of the most common reasons patients discontinue lipid therapy.